Impact of Revi® Implantable Tibial Neuromodulation on Quality of Life in Patients with Urgency Urinary Incontinence
International Urogynecology Journal · 2026
DOI: 10.1007/s00192-026-06538-2 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift International Urogynecology Journal, 2026. Verfasst von Suzette E Sutherland und 3 weiteren Autor:innen. Beteiligte Einrichtung: Arizona Urology Specialists - United Urology Group, Scottsdale, AZ, USA. suzette.sutherland@gmail.com. Hauptthemen laut MEDLINE: Electric Stimulation Therapy, Quality of Life, Tibial Nerve, Urinary Incontinence, Urge. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: BlueWind Medical.
Themen: Inkontinenz
Abstract (Originalsprache)
INTRODUCTION AND HYPOTHESIS: The objective was to evaluate quality-of-life (QoL) improvements following Revi® implantable tibial neuromodulation (ITNM) in patients with urgency urinary incontinence (UUI). METHODS: This prospective, multicenter study evaluated the Revi® System, an ITNM device that allows for at-home therapy using an external, battery-operated unit. The primary efficacy and safety endpoints were assessed at 6 and 12 months; thereafter, participants either exited the study or consented to extend follow-up. This completers analysis evaluated QoL outcomes using the Overactive Bladder Questionnaire (OAB-q) and the total transformed Health-Related QoL (HRQL) score through 24 months. RESULTS: Subfascial implantation of the Revi System was performed in 151 participants. Primary efficacy and safety endpoints were met and no device- or procedure-related serious adverse events occurred. Consistent QoL benefits were seen throughout 24 months, with clinically significant (≥ 10-point change) and sustainable improvements in symptom severity in all domains of the OAB-q and HRQL scores. Additionally, 96.8% reported treatment benefit, 96.7% reported satisfaction, and 100% reported a willingness to continue therapy at 24 months. Notably, among participants who did not meet the primary efficacy endpoint at 24 months (n = 20; 20.6%), appreciable therapeutic benefit was still noted; 83.3% reported treatment benefit, 66.7% reported satisfaction, and 100% reported a willingness to continue this therapy. CONCLUSIONS: Revi is an effective and safe intervention for UUI. Two-year results of the Revi System demonstrate clinically meaningful and sustainable improvements to bladder-related and overall health-related QoL, including those whose objective benefit did not meet the primary efficacy endpoint.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Arizona Urology Specialists - United Urology Group, Scottsdale, AZ, USA. suzette.sutherland@gmail.com.
- Department of Urology, Maastricht UMC, Maastricht, The Netherlands.
- Kaiser Permanente, San Diego, CA, USA.
- Vanderbilt University Medical Center, Nashville, TN, USA.
Förderung
- BlueWind Medical
Zitieren
APA
Sutherland, S. E., Heesakkers, J. P. F. A., Ferrante, K. L., & Dmochowski, R. R. (2026). Impact of Revi® Implantable Tibial Neuromodulation on Quality of Life in Patients with Urgency Urinary Incontinence. International Urogynecology Journal. https://doi.org/10.1007/s00192-026-06538-2
Vancouver
Sutherland SE, Heesakkers JPFA, Ferrante KL, Dmochowski RR. Impact of Revi® Implantable Tibial Neuromodulation on Quality of Life in Patients with Urgency Urinary Incontinence. International Urogynecology Journal. 2026. doi:10.1007/s00192-026-06538-2
BibTeX
@article{Sutherland2026,
author = {Sutherland, Suzette E and Heesakkers, John P F A and Ferrante, Kimberly L and Dmochowski, Roger R},
title = {Impact of Revi® Implantable Tibial Neuromodulation on Quality of Life in Patients with Urgency Urinary Incontinence},
journal = {International Urogynecology Journal},
year = {2026},
doi = {10.1007/s00192-026-06538-2}
}
EUVIMED